<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02267096</url>
  </required_header>
  <id_info>
    <org_study_id>2011-541</org_study_id>
    <nct_id>NCT02267096</nct_id>
  </id_info>
  <brief_title>Lombardi Comprehensive Cancer Center/Legacy Pilot Study to Reduce Adverse Smoking Outcomes in the Context of Lung Cancer Screening</brief_title>
  <official_title>Lombardi Comprehensive Cancer Center/Legacy Pilot Study to Reduce Adverse Smoking Outcomes in the Context of Lung Cancer Screening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prevent Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In 2011, the National Lung Screening Trial (NLST) reported that lung cancer mortality was
      reduced by 20% with spiral computed tomography (CT) compared to chest X-ray. It is estimated
      that 8 million people in the US are at high risk for lung cancer and that lung screening
      could prevent 12,000 deaths annually. Cost effectiveness models suggest that concurrent
      smoking cessation programs will be essential in order to realize the full benefit of
      screening. However, there are no clinical guidelines or evidence-based cessation protocols
      with demonstrated effectiveness in this setting. The investigators are addressing this gap by
      rigorously testing whether two scalable and pragmatic interventions can significantly boost
      intention to quit and cessation rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although abstinence from tobacco remains the best method of lung cancer prevention, recent
      evidence from the National Lung Screening Trial indicated that lung cancer mortality was
      reduced by 20% with spiral computed tomography (CT) compared to chest X-ray. As a result, the
      United States Preventive Services Task Force now recommends lung cancer screening for high
      risk individuals (long-term current and former smokers, 55-80 years old). It is estimated
      that 8 million people in the US are at high risk and that lung screening could prevent 12,000
      deaths annually. Cost effectiveness models suggest that concurrent smoking cessation programs
      will be essential in order to realize the full benefit of screening. However, there are no
      clinical guidelines or evidence-based cessation protocols with demonstrated effectiveness in
      this setting. The investigators propose to address this gap by rigorously testing whether two
      scalable and pragmatic interventions (minimal and moderate in intensity) can significantly
      boost intention to quit and cessation rates. The investigators will capitalize on the
      critical 'teachable moment' of learning of one's screening result. Incorporation of an
      individual's screening result into a cessation intervention will test the innovative question
      of whether intention to quit can be enhanced and reduced intention to quit can be minimized,
      when an individualized, motivational telephone-based intervention is provided. Method: The
      investigators will accrue current smokers from the lung cancer screening programs at three
      sites: Georgetown University Hospital, Lahey Hospital, and Hackensack University Hospital.
      Prior to screening, 100 participants will be consented, enrolled, and will complete the
      baseline (T0) phone interview. Within 1-2 days of receiving the result, participants will be
      randomly assigned to Minimal Treatment (MT) vs. Telephone Counseling (TC). Both arms will
      receive the minimal treatment intervention (a list of print, online, quitline, and in-person
      cessation resources). The TC arm will receive 3-6 sessions of stepped-care, proactive,
      telephone counseling with the same Tobacco Treatment Specialist for both sites. Both arms
      will be assessed at 3-months post randomization for tobacco use outcomes. The specific aims
      are: 1) To conduct a two-arm randomized cessation intervention trial (MT vs. TC) with current
      smokers undergoing screening. 2) The investigators will explore moderators and mediators of
      the interventions' effect on cessation outcomes. Moderators include the screening result,
      race, gender, age, and nicotine dependence. Mediators include teachable moment factors,
      baseline intention to quit, and process measures. Summary: This proof of concept study will
      determine intervention feasibility, effect sizes needed for a larger study, and potential
      moderators and mediators of the intervention. The long-term goal is to evaluate the
      intervention in a multisite trial and ultimately, to disseminate it for use by lung cancer
      screening programs. The innovation of this proposal is in joining disease prevention (smoking
      cessation) with early detection in a medical setting that has relevance for a substantial
      proportion of current smokers, suggesting that even a small increase in cessation has the
      potential for a very large public health benefit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Smoking Status with biochemical verification</measure>
    <time_frame>Measured at 3 months post-randomization</time_frame>
    <description>Self-reported 7-day and 30-day point prevalence abstinence with biochemical verification among those who report having quit smoking.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Timeframe of Participants' Intention to Quit Smoking</measure>
    <time_frame>Measured at each assessment: baseline (T0), 1-2 days post-receipt of screening result (T1), one-month post-randomization (T2), and 3 months post randomization (T2)</time_frame>
    <description>At each assessment, the investigators will ask for the timeframe of participants' intention to quit smoking. The question is worded as: &quot;Next are statements that smokers and former smokers have said about quitting. Please tell me which statement best represents what you think right now.&quot;
1____ I enjoy smoking so much I will never consider quitting no matter what happens 2 ____ I never think about quitting but I might someday 3 ____I rarely think about quitting and have no specific plans to quit 4 ____I sometimes think about quitting but have no specific plans to quit 5 ____I often think about quitting but have no specific plans to quit 6 ____I plan to quit in the next 6 months 7 ____I plan to quit in the next 30 days 8 ____I have already begun to cut down and I have set a quit date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quit attempts</measure>
    <time_frame>Measured at each assessment: baseline (T0), 1-2 days post-receipt of screening result (T1), one-month post-randomization (T2), and 3 months post randomization (T2)</time_frame>
    <description>The questions are worded as follows:
&quot;How many times since our last interview have you quit smoking for 24 hours or longer?&quot;
&quot;What was the LONGEST period of time that you were able to not smoke cigarettes at all since the last interview?&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cigarettes per day</measure>
    <time_frame>Measured at each assessment: baseline (T0), 1-2 days post-receipt of screening result (T1), one-month post-randomization (T2), and 3 months post randomization (T2)</time_frame>
    <description>The question is worded as follows: &quot;Since our last interview, on average, how many cigarettes per day did you smoke?&quot;
i did not smoke since the last interview
less than one per day
1 per day
2-5 per day
6-10 per day
11-20 per day
20 per day
21-40 per day
41-60 per day
more than 3 packs per day</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Smoking</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Telephone Counseling (TC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The TC arm will receive the list of minimal treatment interventions plus 3-6 sessions of stepped-care, proactive, telephone counseling.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minimal Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The minimal treatment intervention includes a list of print, online, national telephone quitline phone number, and in-person cessation resources that is sent to participants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Telephone Counseling</intervention_name>
    <description>The TC arm includes a stepped care approach, 3-6 phone sessions, depending on each participant's needs. Within 1-2 days post-T1 assessment, the intervention will begin. Sessions 1-3 (15 min each) will occur approximately weekly over 3-4 weeks, scheduled at participants' convenience and at strategic therapeutic times (e.g., shortly pre/post-quit date). Continuing smokers or newly quit former smokers who would benefit from relapse prevention sessions will receive up to 3 additional sessions, to be completed within 3-4 weeks. The provision of 3-6 sessions is more intensive than several other telephone counseling interventions. A dose response relationship between quitting and number of sessions has been shown in non-volunteer smokers, and based on our pilot data, the investigators expect that a more intensive intervention will be needed for some participants.</description>
    <arm_group_label>Telephone Counseling (TC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Minimal Treatment</intervention_name>
    <description>A list of self-help materials (print-, web-, phone-based), the national telephone quitline phone number, and local in person cessation resources will be given to all participants.</description>
    <arm_group_label>Telephone Counseling (TC)</arm_group_label>
    <arm_group_label>Minimal Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 55-80 years old

          2. current smoker

          3. &gt; 30-pack years

          4. English-speaking

          5. ability to provide meaningful consent

          6. enrolled to undergo lung cancer screening. -

        Exclusion Criteria:

          1. history of lung cancer

          2. current treatment for other cancer -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Hospital and Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Taylor KL, Cox LS, Zincke N, Mehta L, McGuire C, Gelmann E. Lung cancer screening as a teachable moment for smoking cessation. Lung Cancer. 2007 Apr;56(1):125-34. Epub 2006 Dec 28.</citation>
    <PMID>17196298</PMID>
  </reference>
  <reference>
    <citation>Barry SA, Tammemagi MC, Penek S, Kassan EC, Dorfman CS, Riley TL, Commin J, Taylor KL. Predictors of adverse smoking outcomes in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. J Natl Cancer Inst. 2012 Nov 7;104(21):1647-59. doi: 10.1093/jnci/djs398. Epub 2012 Oct 26.</citation>
    <PMID>23104210</PMID>
  </reference>
  <reference>
    <citation>Tammem√§gi MC, Berg CD, Riley TL, Cunningham CR, Taylor KL. Impact of lung cancer screening results on smoking cessation. J Natl Cancer Inst. 2014 May 28;106(6):dju084. doi: 10.1093/jnci/dju084. Print 2014 Jun.</citation>
    <PMID>24872540</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2014</study_first_submitted>
  <study_first_submitted_qc>October 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2014</study_first_posted>
  <last_update_submitted>October 18, 2016</last_update_submitted>
  <last_update_submitted_qc>October 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Georgetown University</investigator_affiliation>
    <investigator_full_name>Kathryn L. Taylor, Ph.D.</investigator_full_name>
    <investigator_title>Professor, Department of Oncology</investigator_title>
  </responsible_party>
  <keyword>lung cancer screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

